Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Outstanding (Diluted Average): 2022-2025

Historic Shares Outstanding (Diluted Average) for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $353.3 million.

  • Taysha Gene Therapies' Shares Outstanding (Diluted Average) rose 31.92% to $353.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $353.3 million, marking a year-over-year increase of 31.92%. This contributed to the annual value of $250.1 million for FY2024, which is 115.41% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Shares Outstanding (Diluted Average) of $353.3 million as of Q3 2025, which was up 18.56% from $298.0 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Shares Outstanding (Diluted Average) registered a high of $353.3 million during Q3 2025, and its lowest value of $38.2 million during Q1 2022.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $206.5 million, with a median of $232.8 million in 2024.
  • Data for Taysha Gene Therapies' Shares Outstanding (Diluted Average) shows a peak YoY soared of 265.55% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Taysha Gene Therapies' Shares Outstanding (Diluted Average) stood at $44.0 million in 2022, then surged by 164.20% to $116.1 million in 2023, then soared by 115.41% to $250.1 million in 2024, then skyrocketed by 31.92% to $353.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $353.3 million for Q3 2025, versus $298.0 million for Q2 2025 and $269.3 million for Q1 2025.